Entrada Therapeutics, Inc. (TRDA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Entrada Therapeutics reported revenue of $25.4M, down 87.9% from $210.8M the year before. Net income was -$143.8M (a -565.5% net margin), or -$3.47 per diluted share. Operating margin was -621.1%. Operating activities generated -$128.5M of cash, leaving -$129.6M of free cash flow. At fiscal year end, Entrada Therapeutics held $377.4M in total assets against $71.2M in total liabilities, including $90.4M of cash and equivalents.
Open the full interactive Entrada Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Entrada Therapeutics Key Stats
| Share Price | $4.86 |
|---|---|
| Market Cap | $205.2M |
| Revenue YoY Growth | -87.9% |
| 52-Week Range | $4.86 – $16.03 |
| Shares Outstanding | 42.2 million (basic, 2026 Q2) |
Entrada Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $129.0M | $210.8M | $25.4M |
| Operating Income | -$51.1M | -$97.2M | -$3.2M | $47.0M | -$157.9M |
| Pre-Tax Income | -$51.2M | -$94.6M | $12.0M | $66.5M | -$142.8M |
| Income Tax | $0 | $0 | $18.7M | $859,000 | $924,000 |
| Net Income | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M |
| Diluted EPS | -$8.16 | -$3.02 | -$0.20 | $1.68 | -$3.47 |
Entrada Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.6M | $1.3M | $875,000 | $898,000 |
| Net Income | -$44.1M | -$39.2M | -$39.7M | -$42.8M |
| Diluted EPS | -$1.06 | -$0.95 | -$0.95 | -$1.01 |
Entrada Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $291.1M | $45.2M | $67.6M | $101.2M | $90.4M |
| Current Assets | $298.7M | $209.9M | $369.8M | $440.0M | $306.3M |
| Total Assets | $305.8M | $252.1M | $469.2M | $526.3M | $377.4M |
| Current Liabilities | $6.7M | $22.0M | $158.8M | $39.5M | $24.5M |
| Total Liabilities | $7.1M | $39.5M | $226.8M | $97.6M | $71.2M |
| Shareholders' Equity | $298.7M | $212.6M | $242.4M | $428.7M | $306.1M |
Entrada Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$50.9M | -$93.8M | $139.8M | -$41.6M | -$128.5M |
| Cash From Investing | -$4.6M | -$148.7M | -$138.4M | -$27.8M | $116.8M |
| Cash From Financing | $307.5M | $479,000 | $21.0M | $103.0M | $887,000 |
| Free Cash Flow | -$55.4M | -$96.7M | $134.2M | -$44.7M | -$129.6M |
Figures from Entrada Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Entrada Therapeutics financials page for every line item.
Entrada Therapeutics Company Profile
| Ticker | TRDA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001689375 |
Frequently Asked Questions
What was Entrada Therapeutics' revenue in fiscal 2025?
Entrada Therapeutics (TRDA) reported revenue of $25.4M for fiscal 2025.
What is Entrada Therapeutics' annual revenue history?
Entrada Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $129.0M; 2024: $210.8M; 2025: $25.4M.
What was Entrada Therapeutics' net income in fiscal 2025?
Entrada Therapeutics reported net income of -$143.8M for fiscal 2025.
What was Entrada Therapeutics' earnings per share (EPS) in fiscal 2025?
Entrada Therapeutics' diluted EPS was -$3.47 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Entrada Therapeutics generate in fiscal 2025?
Entrada Therapeutics generated -$129.6M of free cash flow in fiscal 2025.
What was Entrada Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Entrada Therapeutics reported revenue of $898,000.
How many shares of Entrada Therapeutics are outstanding?
Entrada Therapeutics reported a weighted average of 42.2 million basic shares outstanding in 2026 Q2.
What is Entrada Therapeutics' market cap?
Based on its latest closing price, Entrada Therapeutics (TRDA) has a market capitalization of about $205.2M.
When does Entrada Therapeutics' fiscal year end?
Entrada Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Entrada Therapeutics headquartered?
Entrada Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.